5 Key Takeaways

• 1

  The FDA has approved ensitrelvir (XOCOVA) for postexposure prophylaxis of COVID-19 in individuals aged 12 and older.

• 2

  Ensitrelvir is the first oral option approved to prevent COVID-19 following exposure to an infected individual.

• 3

  The approval was based on the phase 3 SCORPIO-PEP trial, which enrolled 2,387 participants exposed to symptomatic COVID-19.

• 4

  Ensitrelvir reduced the risk of symptomatic COVID-19 by 67% compared to placebo among uninfected participants.

• 5

  The most common adverse events with ensitrelvir were headache, diarrhea, and cough, with overall rates similar to placebo.